Exploration on the construction of a bladder cancer prognostic model based on disulfidptosis-related lncRNAs and its clinical significance

被引:0
|
作者
Hu, Xian-Cun [1 ]
Yu, Qi-Ying [2 ]
Ding, Hai-Ping [1 ]
Xiao, Feng [3 ]
Gu, Chun-Yan [3 ]
机构
[1] Nantong Univ, Med Sch, Nantong 226007, Jiangsu, Peoples R China
[2] Nantong Univ, Nantong Tumor Hosp, Affiliated Tumor Hosp, Canc Res Ctr, Nantong 226361, Jiangsu, Peoples R China
[3] Nantong Univ, Nantong Peoples Hosp 3, Affiliated Nantong Hosp 3, Dept Pathol, Nantong 226006, Jiangsu, Peoples R China
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
Bladder cancer; Disulfidptosis; lncRNA; TCGA database; Prognosis;
D O I
10.1038/s41598-024-78481-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Disulfidptosis is a novel programmed cell death mode that has been reported to play a role in oncogenesis. Increasing evidences suggest that the long non-coding RNAs (lncRNAs) play crucial roles in the initiation and progression of bladder cancer (BLCA). However, the role and prognostic value of disulfidptosis-related lncRNAs in BLCA remain unknown.The aim of this study was to construct and validate a disulfidptosis-related lncRNA risk model for predicting the prognosis of BLCA patients. A risk model consisting of 5 disulfidptosis-related lncRNAs was developed to predict the prognosis of BLCA patients. The overall survival (OS) of BLCA patients in the high-risk group was significantly shorter than that in the low-risk group (P < 0.05). The effectiveness of this model was validated using the receiver operating characteristic (ROC) curve analysis, and this model proved superior in prognostic accuracy compared with other clinical features. Furthermore, the tumor immune dysfunction and exclusion (TIDE) score in the high-risk group was significantly higher than that in the low-risk group, suggesting that the high-risk group had a less favorable response to immunotherapy. Simultaneously, patients in the low-risk group exhibited significantly higher sensitivity to CTLA-4 monoclonal antibody therapy compared to those in the high-risk group, suggesting potential benefits of immunotherapy for patients in the low-risk group. The combination of high risk and low tumor mutational burden (TMB) could further shortened the OS of BLCA patients. Lastly, the drug sensitivity analysis revealed that the BLCA cells in the high-risk group showed an increased sensitivity to cisplatin, sunitinib, cetuximab, axitinib, docetaxel, saracatinib, vinblastine and pazopanib compared with those in the low-risk group. According to the Quantitative real time PCR results, we found that five lncRNAs of the risk model were more highly expressed in BCa cell lines than human immortalized uroepithelial cell line. The disulfidptosis-related lncRNA risk model has a valuable effect in assessing the prognosis of BLCA patients.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs
    Yang, Xiaoyu
    Zhang, Yunzhi
    Liu, Jun
    Feng, Yougang
    MEDICINE, 2024, 103 (27) : e38750
  • [2] Prognostic model based on disulfidptosis-related lncRNAs for predicting survival and therapeutic response in bladder cancer
    Han, Lirui
    Yang, Hankai
    Jiang, Xuan
    Zhou, Ziyu
    Ge, Chang
    Yu, Kairan
    Li, Guofang
    Wang, Wei
    Liu, Yubo
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [3] Construction of a Prognostic Model for Lung Adenocarcinoma Based on Disulfidptosis-related LncRNAs
    Sun, M.
    Lin, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S493 - S493
  • [4] Construction and validation of a reliable disulfidptosis-related lncRNAs signature of the subtype, prognostic, and immune landscape in bladder cancer
    Leng, Xiaoping
    Chen, Han
    Chen, Gang
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [5] Prognostic value and immune landscapes of disulfidptosis-related lncRNAs in bladder cancer
    Liu, Yijiang
    Tao, Huijing
    Jia, Shengjun
    Wang, Haozheng
    Guo, Long
    Hu, Zhuozheng
    Zhang, Wenxiong
    Liu, Fei
    MOLECULAR AND CLINICAL ONCOLOGY, 2025, 22 (02)
  • [6] Construction of a disulfidptosis-related lncRNAs signature of the subtype, prognostic, and immunotherapy in neuroblastoma
    Fu, Yongcheng
    Zhang, Nan
    Wang, Jingyue
    Wang, Yuanyuan
    Zhang, Da
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (11) : 5909 - 5928
  • [7] Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer
    Xing, Faliang
    Qin, Yi
    Xu, Jin
    Wang, Wei
    Zhang, Bo
    MOLECULAR BIOTECHNOLOGY, 2024, 66 (09) : 2396 - 2414
  • [8] Integrated single-cell analysis reveals the regulatory network of disulfidptosis-related lncRNAs in bladder cancer: constructing a prognostic model and predicting treatment response
    Xiao, Jiafu
    Liu, Wuhao
    Gong, Jianxin
    Lai, Weifeng
    Luo, Neng
    He, Yingfan
    Zou, Junrong
    He, Zhihua
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [9] Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer
    Dong, Xiaoqian
    Liao, Pan
    Liu, Xiaotong
    Yang, Zhenni
    Wang, Yali
    Zhong, Weilong
    Wang, Bangmao
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [10] A disulfidptosis-related lncRNAs cluster to forecast the prognosis and immune landscapes of ovarian cancer
    Wei, Jiahui
    Wang, Ming
    Wu, Yumei
    FRONTIERS IN GENETICS, 2024, 15